Abbott Laboratories $ABT Shares Sold by Cim Investment Management Inc.

Cim Investment Management Inc. lessened its position in Abbott Laboratories (NYSE:ABT) by 55.1% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 4,688 shares of the healthcare product maker’s stock after selling 5,748 shares during the period. Cim Investment Management Inc.’s holdings in Abbott Laboratories were worth $628,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. grew its stake in Abbott Laboratories by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock worth $23,502,644,000 after acquiring an additional 2,977,715 shares during the period. State Street Corp lifted its stake in shares of Abbott Laboratories by 0.9% during the 2nd quarter. State Street Corp now owns 78,354,270 shares of the healthcare product maker’s stock worth $10,656,964,000 after purchasing an additional 689,517 shares during the period. Capital International Investors boosted its holdings in shares of Abbott Laboratories by 2.5% during the third quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock worth $8,251,974,000 after purchasing an additional 1,478,076 shares during the last quarter. Norges Bank purchased a new stake in shares of Abbott Laboratories in the second quarter valued at $3,026,180,000. Finally, Massachusetts Financial Services Co. MA grew its position in shares of Abbott Laboratories by 5.8% in the third quarter. Massachusetts Financial Services Co. MA now owns 15,096,907 shares of the healthcare product maker’s stock valued at $2,022,080,000 after purchasing an additional 821,325 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

NYSE ABT opened at $110.80 on Wednesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. Abbott Laboratories has a 1-year low of $105.27 and a 1-year high of $139.06. The firm has a market capitalization of $192.98 billion, a P/E ratio of 29.79, a P/E/G ratio of 1.75 and a beta of 0.74. The business’s 50-day simple moving average is $113.91 and its 200-day simple moving average is $123.50.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. The firm had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. Abbott Laboratories’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

Insider Buying and Selling at Abbott Laboratories

In related news, EVP Mary K. Moreland sold 613 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the sale, the executive vice president directly owned 104,291 shares of the company’s stock, valued at approximately $12,053,953.78. This represents a 0.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the completion of the transaction, the executive vice president directly owned 146,377 shares in the company, valued at $16,918,253.66. This trade represents a 0.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 3,055 shares of company stock worth $353,097. Corporate insiders own 0.46% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ABT. Oppenheimer reduced their target price on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Evercore dropped their price objective on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Piper Sandler decreased their target price on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research report on Friday, January 23rd. Barclays lowered their target price on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a report on Monday, February 2nd. Finally, Royal Bank Of Canada cut their price target on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $136.16.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.